Login to Your Account

NewCo News

Gemmus Helping Immune System Pace Itself Against Flu

By Anette Breindl
Science Editor

Tuesday, July 3, 2012
San Francisco-based start-up Gemmus Pharma Inc. closed an angel-backed Series A funding round of $1.45 million last week. The company expects the money and the planned second tranche will take its lead compound, GP1001, to a planned 2014 investigational new drug application (IND).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription